Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (34)	4/24/2002 10:17:15 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 123

Anyone...this is where I'm really stupid. Would a 1mL load be considered a big injection? Wilder

To: nigel bates who wrote (34)	4/24/2002 8:13:27 PM
From: mopgcw	Respond to of 123

Morningstar likes the deal: We are encouraged by Biogen's BGEN first-quarter earnings, which met analysts' expectations, as well as the addition of Celltech's CLL drug CDP-571 to Biogen's late-stage pipeline. The company announced Wednesday that worldwide Avonex sales increased 22% from the same quarter in 2001, but we expect this growth rate to decline as we see the effects of competing drug Rebif, which entered the U.S. market in March. The company's saving grace will be its products in late-stage development; it has partnered with Celltech for worldwide commercial rights for CDP-571, a monoclonal antibody to treat Crohn's disease. The drug is in Phase III testing and could reach more than $300 million in annual sales. We will be adjusting our fair value to include this new revenue stream. Jill Kiersky